

Fourth Quarter Full-year 2022 Results



Delivering on our purpose of using the power of leading-edge science to save and improve lives around the world

NYSE: MRK



Strong revenue growth



Strategic business development



Scientific, commercial and operational success



	Worldwide Sales	GAAP EPS	Non-GAAP EPS ¹
Strong Q4 performance reflects continued business momentum	\$13.8B	\$1.18	\$1.62
Full-year 2022 results reflect sustained revenue growth	\$59.3B	\$5.71	\$7.48
2023 financial outlook	\$57.2B to \$58.7B	\$5.86 to \$6.01	\$6.80 to \$6.95

Full-year 2022 Sales

KEYTRUDA
(pembrolizumab) Injection 100 mg

\$20.9B

GARDASIL
(Human Papillomavirus Quadrivalent
(Types 6, 11, 16, and 18) Vaccine, Recombinant)

\$6.9B

GARDASIL.9
Human Papillomavirus
9-valent Vaccine, Recombinant

Lagevrio²
molnupiravir

\$5.7B

MERCK
Animal Health

\$5.5B



“2022 was an exceptional year for Merck, which is a testament to the profound impact our medicines and vaccines are having on patients globally.

I am extremely proud of what our talented and dedicated colleagues have accomplished scientifically, commercially and operationally. Our science-led strategy is working as we continue to build a sustainable engine that will drive innovation and generate long-term value for patients and shareholders well into the next decade.”

Rob Davis
Chairman and Chief Executive Officer, Merck

1. A reconciliation of GAAP to non-GAAP EPS can be found in the company's earnings release.
2. LAGEVRIO is not approved, but is authorized for emergency use by the FDA.